首页 | 本学科首页   官方微博 | 高级检索  
检索        

紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究
引用本文:张献东,韩永军,王东升.紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究[J].实用诊断与治疗杂志,2006,20(2):120-121.
作者姓名:张献东  韩永军  王东升
作者单位:漯河市郾城区人民医院肿瘤内科,河南省,462000
摘    要:目的:观察紫杉醇联合顺铂治疗晚期非小细胞肺癌的近期疗效厦不良反应。方法:国产紫杉醇85mg/m^2静脉滴注第1,8,15d用药;顺铂20mg/m^2静脉滴注1~5d用药。28d为1周期,连用3周期。结果:30例可评价疗效总有效率(CR+PR)53.3%,其中CR1例为初治患者,有效率60%,复治患者有效率33.3%。不良反应为骨髓抑制、脱发、关节肌肉疼痛、消化道反应,其他不良反应轻微均可耐受。结论:紫杉醇联合顺铂治疗晚期非小细胞肺癌可获得较好疗效且不良反应可耐受。

关 键 词:非小细胞肺癌  紫杉醇  顺铂  联合化疗
文章编号:1672-3457(2006)02-120-02
收稿时间:2005-09-24
修稿时间:2005年9月24日

Clinical study on paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer
ZHANG Xiandong,HAN Yongjun,WANG Dongsheng.Clinical study on paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer[J].Journal of Practical Diagnosis and Therapy,2006,20(2):120-121.
Authors:ZHANG Xiandong  HAN Yongjun  WANG Dongsheng
Abstract:Objective To evaluate the results of paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer.Methods Thirty patients with advanced non-small cell lung cancer received paclitaxel 85 mg/m~2 by intravenous infusion on day 1,8,15 and cisplatin 20 mg/m~2 by intravenous infusion on day 1 to 5.The treatment was repeated every 28 days,up to 3 courses.Results Of all cases, 1 got complete response(3.3%),15 got partial response(50%),with an overall rate of(53.3%).The main toxicities were myelosuppression,nausea and vomiting, and other side effects were mild.Conclusion A high response rate can be obtained in advanced non-small cell lung cancer by paclitaxel plus cisplatin.Paclitaxel is a promising antitumor agent with tolerable toxicity
Keywords:Non small cell lung cancer  paclitaxel  cisplatin
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号